--- title: "Annexon (ANNX) news: offering" url: "https://aibio.space/companies/annexon/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ANNX offering news: Annexon proposes $75,000,000 stock offering, prices shares at $2.60. Annexon, Inc. (NASDAQ: ANNX), United States." --- ANNX Annexon, Inc. NASDAQ · United States # Annexon (ANNX) news ANNX offering news Debt Financing · 2026-07-30 ## [Annexon secures credit facility of up to $200 million from Oxford Finance](https://aibio.space/news/annexon-secures-credit-facility-up-200-million-oxford-finance/) Annexon drew $50 million at closing on a credit facility of up to $200 million from Oxford Finance LLC. Another $100 million depends on registrational milestones, and $50 million needs lender approval. ## Latest Annexon news 1. 2026-06-12 Listings [Annexon holders approve raising authorized common shares to 500,000,000](https://aibio.space/news/annexon-holders-approve-raising-authorized-common-shares-500-000-000/) Annexon's stockholders approved raising authorized common stock from 300,000,000 to 500,000,000 shares on June 11, 2026, with 8,795,454 abstentions and no reason given for the increase. 2. 2025-11-12 Financings [Annexon proposes $75,000,000 stock offering, prices shares at $2.60](https://aibio.space/news/annexon-proposes-75-000-000-stock-offering-prices-shares-2-60/) Annexon priced 25,096,153 shares at $2.60 for about $75 million on November 12, 2025, with pre-funded warrants for up to 3,750,000 more shares, and its two lead programs are still in late-stage trials. ## Annexon at a glance - **Ticker**: ANNX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $209.2 million ### Related companies - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) NASDAQ: LSTA - [Vertex Pharmaceuticals](https://aibio.space/companies/vertex-pharmaceuticals/) NASDAQ: VRTX - [Tevogen](https://aibio.space/companies/tevogen/) NASDAQ: TVGN - [Bioxytran](https://aibio.space/companies/bioxytran/) OTC: BIXT - [TRex Bio](https://aibio.space/companies/trex-bio/) NASDAQ: TRXB - [Veru](https://aibio.space/companies/veru/) NASDAQ: VERU - [Aquestive Therapeutics](https://aibio.space/companies/aquestive-therapeutics/) NASDAQ: AQST - [Pasithea Therapeutics](https://aibio.space/companies/pasithea-therapeutics/) NASDAQ: KTTA ### Also on NASDAQ - [Immatics](https://aibio.space/companies/immatics-n-v/) IMTX - [Lifeward](https://aibio.space/companies/lifeward/) LFWD - [Altimmune](https://aibio.space/companies/altimmune/) ALT - [EXOZYMES INC.](https://aibio.space/companies/exozymes/) EXOZ - [Psyence Biomedical](https://aibio.space/companies/psyence-biomedical/) PBM - [PRF Technologies](https://aibio.space/companies/prf-technologies/) PRFX ## Annexon annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$184.7 million](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/) | [$119.4 million](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/) | | Net income (loss) | [-$206.7 million](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/) | [-$138.2 million](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/) | | Cash from operations | [-$186.4 million](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/) | [-$118.0 million](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/) | | Cash and equivalents | [$162.1 million](https://www.sec.gov/Archives/edgar/data/1528115/000119312526346779/) | [$49.5 million](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/) | | Short-term investments | [$76.3 million](https://www.sec.gov/Archives/edgar/data/1528115/000119312526346779/) | [$262.5 million](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $199.3 million, plus short-term investments of $10.0 million, $209.2 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Annexon Has Annexon raised money recently? Our latest story on this, dated Nov 12, 2025: "Annexon proposes $75,000,000 stock offering, prices shares at $2.60". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/annexon-proposes-75-000-000-stock-offering-prices-shares-2-60/). What is the ticker symbol of Annexon? Annexon, Inc. trades under the ticker ANNX on NASDAQ. Where is Annexon listed? Annexon, Inc. is listed on NASDAQ. What is the SEC CIK of Annexon? The SEC Central Index Key (CIK) for Annexon, Inc. is 1528115. Its filings are on SEC EDGAR. How many shares does Annexon have outstanding? 38,563,565 shares as of 2022-05-02, per the cover page of its 10-Q filed 2022-05-09. Which country or territory is Annexon listed under? Our directory records Annexon, Inc. under United States. What does Annexon do? Our directory classifies Annexon, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Annexon? The ISIN recorded for Annexon, Inc. is US03589W1027. Does aibio.space cover Annexon? aibio.space lists Annexon, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Annexon incorporated? SEC records list its state or country of incorporation as DE. Is Annexon profitable? Annexon, Inc. reported a net loss of $206.7 million for the fiscal year ended Dec 31, 2025, and used $186.4 million of cash in operations, per its annual report to the SEC. How much does Annexon spend on research and development? $184.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Annexon have? $209.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Annexon (ANNX) stock news? Our latest story on Annexon, dated Jul 30, 2026: "Annexon secures credit facility of up to $200 million from Oxford Finance". Annexon drew $50 million at closing on a credit facility of up to $200 million from Oxford Finance LLC. Another $100 million depends on registrational milestones, and $50 million needs lender approval. [Source](https://aibio.space/news/annexon-secures-credit-facility-up-200-million-oxford-finance/). Does Annexon have debt, a term loan or convertible notes? Our latest debt story, dated Jul 30, 2026: "Annexon secures credit facility of up to $200 million from Oxford Finance". Annexon drew $50 million at closing on a credit facility of up to $200 million from Oxford Finance LLC. Another $100 million depends on registrational milestones, and $50 million needs lender approval. [Source](https://aibio.space/news/annexon-secures-credit-facility-up-200-million-oxford-finance/). ## Investor discussion: Annexon Members talk about Annexon (ANNX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Annexon, newest first. Each line links the filing it comes from. 1. 2026-06-12 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1528115/000119312526269479/d123141d8k.htm) 2. 2025-11-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1528115/000119312525277669/d34136d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ANNX on TradingView](https://www.tradingview.com/symbols/NASDAQ-ANNX/). ## SEC filings and registration - **SEC name**: Annexon, Inc. - **CIK**: 1528115 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ANNX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1400 SIERRA POINT PARKWAY, BRISBANE, CA, 94005 - **Phone**: (650) 822-5500 - **Shares outstanding**: 38,563,565 as of 2022-05-02 (10-Q filed 2022-05-09) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1528115/000119312526346779/annx-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1528115/000119312526345672/d119960d8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1528115/000119312526342524/d130710d8k.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1528115/000119312526336867/d159969d8k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1528115/000119312526326199/d113783d8k.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1528115/000119312526269479/d123141d8k.htm) filed 2026-06-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1528115/000119312526211931/annx-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1528115/000119312526211863/annx-20260507.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001528115), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Annexon, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ANNX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Annexon, Inc. - **Ticker**: ANNX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US03589W1027 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ANNX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/annexon/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Annexon (ANNX) news: offering", 2026-10-31, https://aibio.space/companies/annexon/